Acticor Biotech Provides an Update on the Us Regulatory Discussion with the FDA
Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular